Aggregated News
A proposal that would let the state share in any profits that result from its $3 billion stem-cell research grants and force researchers to freely disseminate their discoveries has riled biotech executives, who say it could deter them from working on stem-cell therapies.
Several biotech companies and business groups have lodged formal objections to the policy, tentatively adopted in February by the California Institute for Regenerative Medicine, which oversees the stem-cell research effort created in 2004 by Proposition 71.
``These provisions substantially reduce or eliminate the incentives to commercialize patented stem cell-related technologies and products even in spite of the generous funding provided by Proposition 71,'' the Washington-based Biotech Industry Organization complained in a letter to the institute.
In addition, the California Healthcare Institute, which represents biotech firms across the state, warned that deterring companies from participating in stem-cell research could have dire consequences for people suffering from a variety of ailments.
``Without private sector investment in research innovations, stem cell research and the development of resulting new treatments and therapies will be constrained,'' it said.
The comments, which were...
Several biotech companies and business groups have lodged formal objections to the policy, tentatively adopted in February by the California Institute for Regenerative Medicine, which oversees the stem-cell research effort created in 2004 by Proposition 71.
``These provisions substantially reduce or eliminate the incentives to commercialize patented stem cell-related technologies and products even in spite of the generous funding provided by Proposition 71,'' the Washington-based Biotech Industry Organization complained in a letter to the institute.
In addition, the California Healthcare Institute, which represents biotech firms across the state, warned that deterring companies from participating in stem-cell research could have dire consequences for people suffering from a variety of ailments.
``Without private sector investment in research innovations, stem cell research and the development of resulting new treatments and therapies will be constrained,'' it said.
The comments, which were...